SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma gains on reporting 28% rise in Q2 consolidated net profit

20 Nov 2013 Evaluate

Natco Pharma is currently trading at Rs. 784.45, up by 5.35 points or 0.69% from its previous closing of Rs. 779.10 on the BSE.

The scrip opened at Rs. 780.00 and has touched a high and low of Rs. 784.45 and Rs. 775.00 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 826.00 on 14-Nov-2013 and a 52 week low of Rs. 390.00 on 16-May-2013.

Last one week high and low of the scrip stood at Rs. 826.00 and Rs. 756.00 respectively. The current market cap of the company is Rs. 2,461.00 crore.

The promoters holding in the company stood at 56.61% while Institutions and Non-Institutions held 19.43% and 23.96% respectively.

The company has reported 20.19% rise in its net profit at Rs 28.69 crore for the second quarter ended September 30, 2013 as compared to Rs 23.87 crore for the same quarter in the previous year. However, total income from operation of the company has decreased by 1.28% at Rs 150.06 crore for quarter under review as compared to Rs 152.02 crore for the quarter ended September 30, 2012.

On the consolidated basis, the group has registered a growth of 28.25% in net profit after taxes and minority interest of Rs 26.92 crore as compared to Rs 20.99 crore in the same quarter previous year. However, total income from operation of the group has decreased by 0.61% to Rs 179.22 crore for quarter under review as against Rs 180.32 crore in corresponding quarter previous year.

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×